Madrigal Posts $1.83 Third-Quarter EPS
MDGL is trading near its 52-week low of $399 (8.1% above the low) on elevated volume (1.8× avg).
Summary
Madrigal reported third-quarter EPS of $1.83, its first quarterly print since Q2 Rezdiffra net sales of $364.3 million, up 71% year over year, with more than 49,000 patients on therapy. The headline carries only the EPS line, so revenue, guidance and the Rezdiffra trajectory are not yet in hand, though Rezdiffra sales year to date have exceeded $1.0 billion and third-quarter operating income came in at USD 55.989 million. For a company with a roughly $10 billion market value trading above $400 a share, the profit line is the number that matters most after a quarter that was still running a net loss. The Q2 net loss was $57.9 million, so a positive $1.83 EPS implies a sharp swing toward profitability.
At the time of this announcement, MDGL was trading at $431.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10B. The 52-week trading range was $399.00 to $615.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.